Compare Novavax Inc (NVAX) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SAP SE — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while SAP SE trades at $214.78 (market cap $238.67B). The key difference: SAP SE is far larger — about 131.1× Novavax Inc's market cap, and SAP SE pays a 1.38% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and SAP SE for 118 Days on average.
| NVAX | SAP | |
|---|---|---|
Market Cap | $1.82B | $238.67B |
Volume | 6,198,505 | 2,252,662 |
Sector | Health | Technology |
52-Week High | $12.75 | $280.46 |
52-Week Low | $6.22 | $146.38 |
Typical Hold Time | 59 Days | 118 Days |
Enterprise Value | $1.39B | $237.42B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
SAP trades at $212.40, up 1.08% today, with a bullish technical signal from moving averages and strong support at $208. The company reported robust 2025 results with revenue of $36.80B and net income of $7.16B, though Q2 2026 EPS missed expectations. Analyst consensus is a Buy with a $253.40 price target, reflecting optimism in cloud and AI initiatives.
Outlook remains positive driven by cloud revenue growth and AI integration, but risks include competitive pressures and execution challenges. The stock offers upside to consensus targets if margin expansion and deal momentum continue, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
